略過巡覽連結BioView > 關於我們 > 活動情報 > 近期活動檢視

BioAsia Taiwan 2019 - Academia Bio-Innotech Presentation

Taiwan possesses strong biotech talent and R&D base. As PhrMA posted in 2017, Taiwan ranked 3rd among 21 emerging countries for its biotech efforts, in particular in the fields of basic infrastructure, practical research and copyright protection.

活動資訊

For raising the value of the innovative research discoveries, the BioMed Commercialization Center (Drug Division, BMCC|Drug) was set up by Taiwan government with the mission to optimize drug commercialization processes for academic and industry clients in Taiwan.
BioAsia Taiwan will be one of the largest annual biotech events in Asia, BMCC|Drug is delighted to bring these Taiwan Bio-Innotechs to the participants, the professionals from all over the world, to seek collaboration, licensing and investment opportunities.


主辦單位:BioMed Commercialization Center (Drug Division, BMCC|Drug)

時間:2019/7/25(星期四) 13:00~17:00
地點:R402a, 4F, Taipei Nangang Exhibition Center, Hall 1 (TNEC1) (No.1, Jingmao 2nd Rd., Nangang District, Taiepi, Taiwan)

[附件下載]


活動議程

場次 議程內容 主講人
13:00~13:30 Registration
13:30~13:40 Opening Remarks Chi-Feng Chang, Vice President, Development Center for Biotechnology
13:40~13:55 Development of an Autologous Hinge as Universal Ab Lock to Enhance Antibody Drug Selectivity and Safety Humanized Bispecific Antibodies that Link PEGylated Nanoparticles with Tumors for Therapy or Imaging Tian-Lu Cheng, Professor, Kaohsiung Medical University
13:55~14:10 Development of WYC-0209-241 as GSTO Inhibitor for Cancer Therapy Yang-Chang Wu, Chair Professor, China Medical University
14:10~14:25 The Novel αIIbβ3 Antagonist TMV-7 and Its Derivative RR Prevent Thrombosis without the Risk of Bleeding Tur-Fu Huang, Emeritus Professor, Mackay Medical College
14:25~14:40 High Yielding CHO Cell Expression System Hsin-Lin Lu, Research Fellow, Development Center for Biotechnology
14:40~14:55 Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells Hsin-Lin Lu, Research Fellow, Development Center for Biotechnology
14:55~15:10 Adenosine Augmentation Compounds for the Treatment of Neurodegenerative Diseases Yijuang Chern, Distinguished Research Fellow, Academia Sinica
15:10~15:20 Break
15:20~15:35 A New Combinational Treatment Method of TMG/DMG with Ketamine for Psychiatric Disorders Hwei-Hsien Chen, Investigator, National Health Research Institutes
15:35~15:50 Highly Selective HDAC6 Inhibitor MPT0G211, in Preclinical Studies, Available for Licensing or Co-development Shiow-Lin Pan, Professor, Taipei Medical University
15:50~16:05 Development of Antibody Drug AP001 against a Novel Tumor Marker Protein AP for Human Cancer Treatment Wei-Chun HuangFu, Assistant Professor, Taipei Medical University
16:05~16:20 Selective Topo-II Chemotherapeutics Tsai-Kun Li, Professor, National Taiwan University
16:20~16:35 Customizable Particles to Enhance the Immunogenicity of Peptide-based T Cell Vaccines Che-Ming Hu, Assistant Research Fellow, Academia Sinica
16:35~16:50 Development of Anti-lung Cancer Peptide Drug Jinghua Tsai Chang, Assistant Professor, Chung Shan Medical University
16:50~17:00 Closing

報名方式

Please register by JULY 23th via the following link: https://lihi.cc/Soklb

報名費用說明

Registration is free of charge, however, the organizer reserves the right to change the event program and decide upon admitting the participants.
(已截止報名)

會員權益常見問題法律聲明網站地圖友站連結服務條款聯絡我們

版權所有©財團法人生物技術開發中心 產業資訊組

地址:115台北市南港區研究院路一段130巷107號E棟 會員專線:(02)7700-3800#5228